title: Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia.
abstract: OBJECTIVE
  The present study was designed to evaluate the lipid-altering efficacy, safety, and tolerability of lovastatin treatment in adolescent girls with heterozygous familial hypercholesterolemia.
  
  
  METHODS
  A total of 54 postmenarchal girls, aged 10 to 17 years, were enrolled in a 24-week, double-blind, randomized, placebo-controlled study. After a 4-week diet/placebo run-in period, patients were randomized to 1 of 2 groups: (1) treatment with diet plus lovastatin 20 mg/day for 4 weeks, followed by diet plus lovastatin 40 mg/day for 20 weeks, or (2) diet plus placebo for 24 weeks.
  
  
  RESULTS
  Baseline values of lipids, lipoproteins, and apolipoproteins (apo) were comparable between treatment groups. Lovastatin treatment was efficacious at reducing low-density lipoprotein cholesterol by 23% to 27%, total cholesterol by 17% to 22%, and apo B by 20% to 23% at weeks 4 and 24, respectively. Between-treatment group differences were not statistically significant for triglycerides, very-low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, or apo A-I. Lovastatin was generally safe and well tolerated. There were no clinically significant alterations in vital signs (blood pressure and pulse rate), anthropomorphic measurements (height, weight, and BMI), hormone levels (luteinizing hormone, follicle-stimulating hormone, dehydroepiandrosterone sulfate, estradiol, and cortisol), menstrual cycle length, or tests of liver and muscle function.
  
  
  CONCLUSIONS
  Lovastatin offers an efficacious and well-tolerated treatment option for improving lipid profiles in adolescent girls with familial hypercholesterolemia.
authors.affiliation: The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA. sclauss@cnmc.org
authors.forename: Sarah B
authors.initials: SB
authors.lastname: Clauss
authors.forename: Kathryn W
authors.initials: KW
authors.lastname: Holmes
authors.forename: Paul
authors.initials: P
authors.lastname: Hopkins
authors.forename: Evan
authors.initials: E
authors.lastname: Stein
authors.forename: Meehyung
authors.initials: M
authors.lastname: Cho
authors.forename: Ann
authors.initials: A
authors.lastname: Tate
authors.forename: Amy O
authors.initials: AO
authors.lastname: Johnson-Levonas
authors.forename: Peter O
authors.initials: PO
authors.lastname: Kwiterovich
mesh_terms: D000293:Adolescent; D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001053:Apolipoproteins / Q000097:blood; D002648:Child; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D006128:Growth / Q000187:drug effects; D006579:Heterozygote; D006728:Hormones / Q000097:blood; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008148:Lovastatin / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000924:Anticholesteremic Agents; D001053:Apolipoproteins; D008078:Cholesterol, LDL; D006728:Hormones; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D008074:Lipoproteins; D008148:Lovastatin